Mobile website
Tumor vesselspecific antibody ScFvH1: Targeting efficiency and antitumor ability
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
To investigate the targeting and antitumor ability of the tumor vesselspecific antibody ScFvH1 selected from phageScFv library, and to discuss the application of the antibody in clinical diagnosis and therapy of cancer. Methods: The ScFvH1 gene was inserted into pET28a(+)/EGFP vector containing green fluorescent protein(GFP) gene and pTIGTrx vector containing thioredoxin gene; the products were then expressed in E.coli and purified by using NiNTA. Tumorbearing mice model was established by subcutanuous injection of cervical cancer cell line HeLa. The mice were injected with purified ScFvEGFP fusion protein through vena caudalis and the GFP signals were observed by fluorescent microscope to evaluate the targeting ability of the antibody. Meanwhile, the mice model also received intratumoral injection of purified ScFvEGFP fusion protein to evaluate the antitumor effect of the antibody. Results: Soluble ScFvH1 gene and ScFvH1EGFP protein were successfully expressed in E.coli; a single band was showed in SDSPAGE after the purification by NiNTA. We found that ScFvH1EGFP fusion protein was enriched to tumor tissues, but there was only weak fluorescent signal when EGFP protein was injected. No EGFP signal was observed in the lung of tumorbearing mice. Tumor inhibition experiment showed that the tumor growth in the antibody treatment group was similar to that of the PBS control group. Conclusion: The tumor vesselspecific antibody ScFvH1 selected from phageScFv library can specifically target tumor vessels, but it has no obvious inhibitory effect on tumor growth. Our findings pave a way for antibody in cancer diagnosis and treatment.
Keywords:
Project Supported:
Clc Number:
